Skip to main content
. Author manuscript; available in PMC: 2011 May 1.
Published in final edited form as: Clin Cancer Res. 2010 Apr 20;16(9):2591–2604. doi: 10.1158/1078-0432.CCR-09-2443

Fig 6.

Fig 6

Doxorubicin and TRAIL combination modulates angiogenesis-related factor expression in STS cells. A) STS cells grown in culture were treated with doxorubicin (0.1μM/24hr), TRAIL (25μg/ml/12hr), or their combination. qRTPCR demonstrated a significant increase in CXCL10 mRNA levels (*p<0.05) and a decrease in IL-8 mRNA expression (*p<0.05); B) Conditioned media was collected from STS cells treated as above and was subjected to ELISA. A significant increase in CXCL10 protein expression (*p<0.05) and a decrease in IL8 protein levels (*p<0.05) were observed. Graphs represent the average of three repeated experiments ±SD.